flufenamic acid has been researched along with Neoplasms in 5 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flufenamic acid (FA) was reported to bind in a liphophilic TEAD palmitic acid (PA) pocket, leading to reduction of the expression of Axl and NF2." | 1.91 | Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings. ( Allali-Hassani, A; Allemand, F; Annabi, B; Barsyte-Lovejoy, D; Bolotokova, A; Cotelle, P; Fnaiche, A; Gagnon, A; Gelin, M; Guichou, JF; LaPlante, SR; Li, F; Mélin, L; Paquin, A; Santhakumar, V; Suárez, NG; Vedadi, M; Vu, V; Woo, S, 2023) |
| " The drug likeliness of the best compounds was also evaluated in silico to ensure the bioavailability of these compounds particularly LG1 as compared to FLU thus providing a strong rationale for their development as leads against TEAD." | 1.62 | Exploring TEAD2 as a drug target for therapeutic intervention of cancer: A multi-computational case study. ( Kumar, A; Misra, G; Pal, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Zemanova, L | 1 |
| Hofman, J | 1 |
| Novotna, E | 1 |
| Musilek, K | 1 |
| Lundova, T | 1 |
| Havrankova, J | 1 |
| Hostalkova, A | 1 |
| Chlebek, J | 1 |
| Cahlikova, L | 1 |
| Wsol, V | 1 |
| Fnaiche, A | 1 |
| Mélin, L | 1 |
| Suárez, NG | 1 |
| Paquin, A | 1 |
| Vu, V | 1 |
| Li, F | 1 |
| Allali-Hassani, A | 1 |
| Bolotokova, A | 1 |
| Allemand, F | 1 |
| Gelin, M | 1 |
| Cotelle, P | 1 |
| Woo, S | 1 |
| LaPlante, SR | 1 |
| Barsyte-Lovejoy, D | 1 |
| Santhakumar, V | 1 |
| Vedadi, M | 1 |
| Guichou, JF | 1 |
| Annabi, B | 1 |
| Gagnon, A | 1 |
| Pal, R | 1 |
| Kumar, A | 1 |
| Misra, G | 1 |
| Kater, RM | 1 |
1 review available for flufenamic acid and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
1 trial available for flufenamic acid and Neoplasms
| Article | Year |
|---|---|
Double-blind evaluation of the analgesic and toxic effects of flufenamic acid and mefenamic acid in patients with chronic pain.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Flufenamic Acid; Fluorine; Humans; Mefenamic Acid; | 1968 |
3 other studies available for flufenamic acid and Neoplasms
| Article | Year |
|---|---|
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Apigenin; Daunorubicin; Enzyme Inhibitors; Flavones; Flavo | 2015 |
Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.
Topics: Flufenamic Acid; Gene Expression Regulation; Hippo Signaling Pathway; Humans; Neoplasms; Transcripti | 2023 |
Exploring TEAD2 as a drug target for therapeutic intervention of cancer: A multi-computational case study.
Topics: Binding Sites; Crystallization; DNA-Binding Proteins; Drug Discovery; Flufenamic Acid; Humans; Hydro | 2021 |